<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Carbapenems</title><meta name="description" content="Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Carbapenem"/><meta property="og:title" content="Carbapenems"/><meta property="og:description" content="Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents..."/><meta property="og:url" content="https://grokipedia.com/page/Carbapenem"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Carbapenems"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.996Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Carbapenems"/><meta name="twitter:description" content="Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="6e8939a69333122c51d06d58c9635817-ea38887f57af415c-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=6e8939a69333122c51d06d58c9635817,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.1058905737752136,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#carbapenems" class="transition-opacity hover:opacity-100 opacity-50">Carbapenems</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medical-uses" class="transition-opacity hover:opacity-100 opacity-50">Medical uses</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#intra-abdominal-infections" class="transition-opacity hover:opacity-100 opacity-50">Intra-abdominal infections</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#complicated-urinary-tract-infections" class="transition-opacity hover:opacity-100 opacity-50">Complicated urinary tract infections</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pneumonia" class="transition-opacity hover:opacity-100 opacity-50">Pneumonia</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#bloodstream-infections" class="transition-opacity hover:opacity-100 opacity-50">Bloodstream infections</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#spectrum-of-activity" class="transition-opacity hover:opacity-100 opacity-50">Spectrum of activity</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#gram-negative-pathogens" class="transition-opacity hover:opacity-100 opacity-50">Gram-negative pathogens</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#gram-positive-pathogens" class="transition-opacity hover:opacity-100 opacity-50">Gram-positive pathogens</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other" class="transition-opacity hover:opacity-100 opacity-50">Other</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#contraindications" class="transition-opacity hover:opacity-100 opacity-50">Contraindications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Adverse effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#approved-for-clinical-use" class="transition-opacity hover:opacity-100 opacity-50">Approved for clinical use</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#unapprovedexperimental" class="transition-opacity hover:opacity-100 opacity-50">Unapproved/experimental</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#bacterial-resistance" class="transition-opacity hover:opacity-100 opacity-50">Bacterial resistance</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#enterobacteriaceae" class="transition-opacity hover:opacity-100 opacity-50">Enterobacteriaceae</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pseudomonas-aeruginosa-and-acinetobacter-baumannii" class="transition-opacity hover:opacity-100 opacity-50">Pseudomonas aeruginosa and Acinetobacter baumannii</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#structure" class="transition-opacity hover:opacity-100 opacity-50">Structure</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biosynthesis" class="transition-opacity hover:opacity-100 opacity-50">Biosynthesis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#administration" class="transition-opacity hover:opacity-100 opacity-50">Administration</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="carbapenems" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Carbapenems<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Carbapenems</strong> are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are generally resistant to many beta-lactamases that inactivate other beta-lactam antibiotics.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenem antibiotics were originally developed at Merck &amp; Co. from the carbapenem thienamycin, a naturally derived product of <em>Streptomyces cattleya</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Ongoing global concern exists over the continued increase in rates of resistance to carbapenems, as there are few therapeutic options for treating infections caused by carbapenem-resistant bacteria (such as <em>Klebsiella pneumoniae</em> and other carbapenem-resistant Enterobacteriaceae<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup>).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> As of 2023, carbapenem resistance among Enterobacteriaceae in the EU/EEA has risen to a population-weighted mean of 13.3%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup>: <a href="https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf</a></span>
<h2 id="medical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Medical uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="intra-abdominal-infections" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Intra-abdominal infections<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The carbapenem ertapenem is one of several first-line agents recommended by the Infectious Diseases Society of America (IDSA) for the empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity in low-risk patients, per 2024 guidelines. Agents with anti-pseudomonal activity, such as imipenem and meropenem, are not recommended for this population to minimize resistance development. Imipenem and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal infections that are healthcare-associated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="complicated-urinary-tract-infections" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Complicated urinary tract infections<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A 2020 systematic review and meta-analysis found carbapenems, particularly meropenem, to be effective for complicated urinary tract infections (cUTIs), with high clinical cure rates comparable to newer antibiotics, including in cases with multidrug-resistant pathogens. Earlier 2015 reviews noted limited evidence for optimal regimens but supported efficacy in levofloxacin-resistant <em>E. coli</em> infections; however, doripenem is no longer available in many markets, including the US since 2018.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h3 id="pneumonia" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pneumonia<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The carbapenems imipenem and meropenem are included among options recommended by the American Thoracic Society (ATS) and IDSA as empiric therapy for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), particularly in late-onset cases or when <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter</em>, or extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are suspected, per 2016 guidelines. Monotherapy is preferred unless local resistance exceeds 10-20% or the patient is in septic shock; routine combination therapy with an aminoglycoside is not recommended due to toxicity risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenems are infrequently used for community-acquired pneumonia (CAP), as most pathogens (<em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, atypicals, Enterobacteriaceae) respond to narrower agents like fluoroquinolones, amoxicillin, or azithromycin. Imipenem and meropenem may be considered in severe CAP with risk factors for <em>P. aeruginosa</em> (e.g., structural lung disease), per 2019 IDSA/ATS guidelines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h3 id="bloodstream-infections" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Bloodstream infections<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A 2015 meta-analysis concluded that the anti-pseudomonal penicillin-beta-lactamase inhibitor combination piperacillin-tazobactam gives results equivalent to treatment with a carbapenem in patients with sepsis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In 2015, the National Institute for Health and Care Excellence recommended piperacillin-tazobactam as first-line therapy for the treatment of bloodstream infections in neutropenic cancer patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For bloodstream infections known to be due to extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenems are superior to alternative treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<h3 id="spectrum-of-activity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Spectrum of activity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenems exhibit broad-spectrum activity against gram-negative bacteria and somewhat narrower activity against gram-positive bacteria. For empiric therapy, they are often combined with a second drug for broader gram-positive coverage. Use should be guided by local resistance patterns and antimicrobial stewardship to address rising carbapenem-resistant Enterobacteriaceae (CRE), per 2024 IDSA guidance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h4 id="gram-negative-pathogens" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Gram-negative pathogens<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">The spectrum of activity of the carbapenems imipenem and meropenem includes most Enterobacteriaceae species, including <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Enterobacter cloacae</em>, <em>Citrobacter freundii</em>, <em>Proteus mirabilis</em>, and <em>Serratia marcescens</em>. Activity is maintained against most strains of <em>E. coli</em> and <em>K. pneumoniae</em> that are resistant to cephalosporins due to the production of extended-spectrum beta-lactamases. Imipenem and meropenem also exhibit good activity against most strains of <em>Pseudomonas aeruginosa</em> and <em>Acinetobacter</em> species. The observed activity against these pathogens is especially valued as they are intrinsically resistant to many other antibiotic classes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h4 id="gram-positive-pathogens" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Gram-positive pathogens<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">The spectrum of activity of the carbapenems against gram-positive bacteria is fairly broad, but not as exceptionally so as in the case of gram-negative bacteria. Good activity is seen against methicillin-sensitive strains of <em>Staphylococcus</em> species, but many other antibiotics provide coverage for such infections. Good activity is also observed for most <em>Streptococcus</em> species, including penicillin-resistant strains. Carbapenems are not highly active against methicillin-resistant <em>Staphylococcus aureus</em> or most enterococcal infections because carbapenems do not bind to the penicillin-binding protein used by these pathogens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h4 id="other" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Other<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenems generally exhibit good activity against anaerobes such as <em>Bacteroides fragilis</em>. Like other beta-lactam antibiotics, they lack activity against atypical bacteria, which do not have a cell wall and are thus not affected by cell wall synthesis inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h2 id="contraindications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Contraindications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenems are contraindicated in patients with prior allergic reactions to beta lactam antibiotics. In addition, as the intramuscular formulations of ertapenem and imipenem are formulated with lidocaine, the intramuscular formulation of these two drugs are contraindicated in patients with prior adverse reactions to lidocaine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Furthermore, concomitant use of carbapenems with valproic acid is generally not recommended, as it has been shown to decrease valproic acid concentrations by as much as 90%, potentially leading to breakthrough seizures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h2 id="adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Adverse effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Serious and occasionally fatal allergic reactions can occur in people treated with carbapenems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Seizures are a dose-limiting toxicity for imipenem, while the risk is lower for meropenem.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Clostridioides difficile-related diarrhea may occur in people treated with carbapenems or other broad-spectrum antibiotics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Although those with an allergy to penicillin may develop cross-sensitivity to carbapenems, the rate is low (less than 1% in patients with confirmed IgE-mediated penicillin allergy).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h3 id="approved-for-clinical-use" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Approved for clinical use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Imipenem</span>, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_32eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Imipenem is hydrolyzed in the <span class="inline text-[1em] leading-7">mammalian kidney</span> by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor <span class="inline text-[1em] leading-7">cilastatin</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Imipenem is available in both intravenous<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> and intramuscular<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> formulations.</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Meropenem</span> is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against gram-positive pathogens, and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of seizures in a phase 2 trial, meropenem is effective for the treatment of bacterial meningitis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_34eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> A systematic review performed by an employee of the company that markets meropenem concluded that it provides a higher bacterial response and lower adverse event rates than imipenem in people with severe infections, but no difference in mortality rate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Ertapenem</span> is administered once daily as an intravenous infusion or intramuscular injection. It lacks useful activity against the <em>P. aeruginosa</em> and <em>Acinetobacter</em> species, both of which are important causes of hospital-acquired infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_76eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Doripenem</span>, approved in the United States in 2007, has a spectrum of activity very similar to that of meropenem. Its greater stability in solution allows the use of prolonged infusions and it is somewhat less likely to produce seizures than other carbapenems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> However, it was discontinued from the US market in 2014 following FDA warnings about increased mortality risk in ventilator-associated pneumonia, though it remains approved for complicated intra-abdominal and urinary tract infections.</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Panipenem/betamipron</span> (Japanese approval 1993)</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Biapenem</span> (Japanese approval 2001) exhibits similar efficacy and adverse event rates as other carbapenems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Tebipenem</span> pivoxil (Japanese approval 2009 for pediatric use) is the first carbapenem whose prodrug form, the pivalyl ester, is orally available.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3eeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Faropenem</span> medoxomil, approved in Japan in 1997 and in India in 2003, is an oral penem antibiotic for respiratory and urinary tract infections; it has not been approved in the United States.</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Sulopenem</span> etzadroxil/probenecid (Orlynvah), approved in the United States in October 2024, is an oral penem for uncomplicated urinary tract infections in adult women caused by susceptible bacteria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></li>
</ul>
<h3 id="unapprovedexperimental" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Unapproved/experimental<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Razupenem</span> (PZ-601)
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">PZ-601 is a carbapenem antibiotic currently being tested as having a broad spectrum of activity including strains resistant to other carbapenems. Despite early Phase II promise, Novartis (who acquired PZ-601 in a merger deal with Protez Pharmaceuticals) recently dropped PZ-601, citing a high rate of adverse events in testing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19ifabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></li>
</ul>
</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Lenapenem</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Tomopenem</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Thienamycin</span> (thienpenem) the first discovered carbapenem</li>
</ul>
<h1 id="bacterial-resistance" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Bacterial resistance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="enterobacteriaceae" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Enterobacteriaceae<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7"><em>Enterobacteriaceae</em> are common pathogens responsible for urinary tract infections,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> abdominal infections,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> and hospital-acquired pneumonia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Beta lactam resistance in these pathogens is most commonly due to the expression of beta lactamase enzymes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Between 2007 and 2011, the percentage of <em>Escherichia coli</em> isolates from Canadian hospitals that produce <span class="inline text-[1em] leading-7">extended spectrum beta lactamases</span> (ESBL) increased from 3.4% to 4.1%; among <em>Klebsiella pneumoniae</em> isolates ESBL producers increased from 1.5% to 4.0%. These strains are resistant to <span class="inline text-[1em] leading-7">third generation cephalosporins</span> that were developed for the treatment of beta lactamase-producing <em>Enterobacteriaceae</em> and carbapenems are generally regarded as the treatment of choice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> More recently, many countries have experienced a dramatic upswing in the prevalence of <em>Enterobacteriaceae</em> that produce both ESBLs and <span class="inline text-[1em] leading-7">carbapenemases</span> such as the Klebsiella pneumoniae carbapenemase (KPC). As of 2013, 70% of Greek <em>Klebsiella pneumoniae</em> isolates were resistant to third generation cephalosporins and 60% were resistant to carbapenems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_khabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> As of 2023, resistance rates in Greece remain elevated at approximately 81.5% to third-generation cephalosporins and 69.7% to carbapenems, while the EU/EEA population-weighted mean for carbapenem resistance in <em>K. pneumoniae</em> has increased to 13.3% (from 10.4% in 2019), with bloodstream infection incidence rising 57.5% over the same period.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> The growing prevalence and difficulty of treating such multi-drug resistant <em>Enterobacteriaceae</em> has led to a renaissance of the use of antibiotics such as <span class="inline text-[1em] leading-7">colistin</span>, which was discovered in the 1950s but rarely used until recently due to unattractive levels of toxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_uhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> However, colistin resistance is now emerging, further complicating treatment options. Carbapenem-resistant <em>Enterobacteriaceae</em> (CRE) are designated a critical priority by the World Health Organization due to their global threat.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Prevalence of carbapenem-resistant <em>Enterobacteriaceae</em> in paediatric intensive care units (Cairo, Egypt) was 24% and various genes of carbapenemases were detected in 80% of carbapenem-resistant <em>Enterobacteriaceae</em> with dominance of <em>bla</em> OXA-48.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<h2 id="pseudomonas-aeruginosa-and-acinetobacter-baumannii" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]"><em>Pseudomonas aeruginosa</em> and <em>Acinetobacter baumannii</em><button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Infections caused by the non-fermenting gram-negative bacteria <em>Pseudomonas aeruginosa</em> and <em>Acinetobacter baumannii</em> are most commonly encountered in hospitalized people. These bacteria exhibit an unusually high level of intrinsic resistance to antibiotics due to their expression of a wide range of resistance mechanisms. Antibiotics cross the outer membrane of <em>Pseudomonas</em> and <em>Acinetobacter</em> approximately 100 times more slowly than they cross the outer membrane of <em>Enterobacteriaceae</em> , due in part to their use of <span class="inline text-[1em] leading-7">porins</span> that can adopt a conformation having a very restricted entry channel. Further, the porin levels may be down-regulated in response to antibiotic exposure. Antibiotic molecules that successfully traverse the porin channels may be removed by efflux pumps. Downregulation of the porin OprD2 is an important contributor to imipenem resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Like the <em>Enterobacteriaceae</em> , <em>Pseudomonas</em> and <em>Acinetobacter</em> can express a wide range of antibiotic-deactivitating enzymes, including beta lactamases. <em>Pseudomonas</em> produces an inducible broad spectrum beta lactamase, AmpC, that is produced in response to beta lactam exposure. The combination of inducible AmpC expression, poor membrane permeability, and efflux pumps make <em>Pseudomonas</em> resistant to most beta lactams. The clinical efficacy of carbapenems in <em>Pseudomonas</em> infection arises in part because, while they are strong inducers of AmpC, they are poor substrates. The identification of <em>Pseudomonas</em> strains that produce beta lactamases capable of cleaving carbapenems has raised increasing concern regarding the potential for an era of untreatable <em>Pseudomonas</em> infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ijabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h2 id="structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenem (formula <span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>C</mi><mn>7</mn></msub><msub><mi>H</mi><mn>7</mn></msub><mi>N</mi><msub><mi>O</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">C_7 H_7 N O_3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:0.8333em;vertical-align:-0.15em"></span><span class="mord"><span class="mord mathnormal" style="margin-right:0.07153em">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.0715em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">7</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathnormal" style="margin-right:0.08125em">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.0813em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">7</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span><span class="mord mathnormal" style="margin-right:0.10903em">N</span><span class="mord"><span class="mord mathnormal" style="margin-right:0.02778em">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.0278em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">3</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span></span></span></span>, CAS registry number 78854-41-8) is the parent of this class of compounds. The parent is only of theoretical interest. The carbapenems are very similar to the penicillins (penams): the sulfur in penams is replaced with methylene and an unsaturation has been introducedâ€”hence the name of the group, the carbapen<em>ems</em>.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenems are further broken down into groups with ertapenem being the lone member of group 1. Group 2 carbapenems (imipenem, meropenem, and doripenem) are identified by their efficacy with respect to multiresistant gram-negative (MDRGN) bacteria such as <em>Pseudomonas</em> and <em>Acinetobacter</em> species.</span>
<h2 id="biosynthesis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Biosynthesis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The carbapenems are thought to share their early biosynthetic steps in which the core ring system is formed. <span class="inline text-[1em] leading-7">Malonyl-CoA</span> is condensed with <span class="inline text-[1em] leading-7">glutamate-5-semialdehyde</span> with concurrent formation of the five-membered ring. Next, a Î²-lactam synthetase uses <span class="inline text-[1em] leading-7">ATP</span> to form the Î²-lactam and the saturated <span class="inline text-[1em] leading-7">carbapenam</span> core. Further oxidation and ring inversion provides the basic carbapenem.</span>
<h2 id="administration" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Administration<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Due to their expanded spectra, the desire to avoid generation of resistance and the fact that, in general, they have poor oral bioavailability, they are administered intravenously in hospital settings for more serious infections. As of October 2025, the oral carbapenem prodrug tebipenem HBr has demonstrated non-inferiority to intravenous therapy in a Phase III trial for complicated urinary tract infections, with the trial stopped early for efficacy; regulatory filing is planned for Q4 2025, potentially making it the first approved oral carbapenem.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sneader, Walter (2006). <em>Drug Discovery-A History</em>. Wiley. p. 310. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-471-89980-8.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Birnbaum J, Kahan FM, Kropp H, MacDonald JS (June 1985). &quot;Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin&quot;. <em><span class="inline text-[1em] leading-7">American Journal of Medicine</span></em>. <strong>78</strong> (6A): 3â€“21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0002-9343%2885%2990097-X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0002-9343(85)90097-X</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0002-9343" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0002-9343</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3859213" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3859213</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://outbreaknewstoday.com/brazil-klebsiella-pneumoniae-carbapenemase-prompts-closing-of-hospital-icu-51544/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Brazil: Klebsiella pneumoniae carbapenemase prompts closing of hospital ICU - Outbreak News Today&quot;</a>. 2015-07-26.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E (2013). &quot;Carbapenems&quot;. <em>J Chemother</em>. <strong>25</strong> (1): 1â€“17. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1179%2F1973947812Y.0000000032" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1179/1973947812Y.0000000032</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23433439" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23433439</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:218660238" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">218660238</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenems: past, present, and future&quot;</a>. <em>Antimicrob. Agents Chemother</em>. <strong>55</strong> (11): 4943â€“60. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.00296-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.00296-11</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3195018</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21859938" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21859938</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Livermore DM, Woodford N (October 2000). &quot;Carbapenemases: a problem in waiting?&quot;. <em><span class="inline text-[1em] leading-7">Current Opinion in Microbiology</span></em>. <strong>3</strong> (5): 489â€“95. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS1369-5274%2800%2900128-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S1369-5274(00)00128-4</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1369-5274" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1369-5274</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11050448" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11050448</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O&#x27;Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). <a href="https://doi.org/10.1086%2F649554" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America&quot;</a>. <em>Clin. Infect. Dis</em>. <strong>50</strong> (2): 133â€“64. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F649554" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/649554</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20034345" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20034345</a>.</span></div></li><li id="https://www.idsociety.org/practice-guideline/intra-abdominal-infections/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.idsociety.org/practice-guideline/intra-abdominal-infections/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.idsociety.org/practice-guideline/intra-abdominal-infections/</a></span></div></li><li id="https://academic.oup.com/ofid/article/9/5/ofaa480/5920690" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ofid/article/9/5/ofaa480/5920690" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ofid/article/9/5/ofaa480/5920690</a></span></div></li><li id="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing</a></span></div></li><li id="https://www.idsociety.org/practice-guideline/hap_vap/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.idsociety.org/practice-guideline/hap_vap/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.idsociety.org/practice-guideline/hap_vap/</a></span></div></li><li id="https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST</a></span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Shiber S, Yahav D, Avni T, Leibovici L, Paul M (2015). <a href="https://doi.org/10.1093%2Fjac%2Fdku351" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Î²-Lactam/Î²-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials&quot;</a>. <em>J. Antimicrob. Chemother</em>. <strong>70</strong> (1): 41â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdku351" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dku351</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25261419" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25261419</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">National Collaborating Centre for Cancer (UK) (2012). <a href="https://www.ncbi.nlm.nih.gov/books/NBK299128/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients - National Library of Medicine - PubMed Health</em></a>. National Institute for Health and Care Excellence: Guidance. National Institute for Health and Clinical Excellence (UK). <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26065059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26065059</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012). <a href="https://doi.org/10.1093%2Fjac%2Fdks301" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum Î²-lactamases: a systematic review and meta-analysis&quot;</a>. <em>J. Antimicrob. Chemother</em>. <strong>67</strong> (12): 2793â€“803. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdks301" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dks301</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22915465" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22915465</a>.</span></div></li><li id="https://www.idsociety.org/practice-guideline/amr-guidance/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.idsociety.org/practice-guideline/amr-guidance/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.idsociety.org/practice-guideline/amr-guidance/</a></span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20170118192239/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;www.accessdata.fda.gov&quot;</a> (PDF). Archived from <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on January 18, 2017.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;www.accessdata.fda.gov&quot;</a> (PDF).M</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Herrero, Miranda (2015). &quot;Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?&quot;. <em>European Journal of Paediatric Neurology</em>. <strong>19</strong> (2): 155â€“61. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ejpn.2014.12.010" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ejpn.2014.12.010</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25578527" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25578527</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Torres MJ, Blanca M (2010). &quot;The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams&quot;. <em>Med. Clin. North Am</em>. <strong>94</strong> (4): 805â€“20, xii. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.mcna.2010.04.006" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.mcna.2010.04.006</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20609864" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20609864</a>.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Slama TG (2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use&quot;</a>. <em>Crit Care</em>. <strong>12</strong> (5): 233. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Fcc6994" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/cc6994</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2592734</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18983709" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18983709</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Slimings C, Riley TV (2014). <a href="https://doi.org/10.1093%2Fjac%2Fdkt477" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis&quot;</a>. <em>J. Antimicrob. Chemother</em>. <strong>69</strong> (4): 881â€“91. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdkt477" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dkt477</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24324224" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24324224</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20160417213010/http://www.vhpharmsci.com/VHFormulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Pharmaceutical Sciences CSU Parenteral Antibiotic Allergy cross-sensitivity chart&quot;</a> (PDF). Vancouver Acute Pharmaceutical Sciences, Vancouver Hospital &amp; Health Sciences Centre. 2016. Archived from <a href="http://www.vhpharmsci.com/vhformulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on April 17, 2016. Retrieved May 19, 2017.</span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/31170539/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/31170539/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/31170539/</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">PRIMAXIN (Brand Name Drug) FDA Application No. (NDA) 050587 Drug Details, Drugs@FDA</a></span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20121016180424/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;www.accessdata.fda.gov&quot;</a> (PDF). Archived from <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on October 16, 2012.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;www.accessdata.fda.gov&quot;</a> (PDF).</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zhanel GG, Simor AE, Vercaigne L, Mandell L (1998). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects&quot;</a>. <em>Can J Infect Dis</em>. <strong>9</strong> (4): 215â€“28. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1155%2F1998%2F831425" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1155/1998/831425</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3250889</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22346545" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22346545</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Edwards SJ, Emmas CE, Campbell HE (2005). &quot;Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections&quot;. <em>Curr Med Res Opin</em>. <strong>21</strong> (5): 785â€“94. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1185%2F030079905X46223" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1185/030079905X46223</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15969878" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15969878</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:7654496" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7654496</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20151106073454/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;www.accessdata.fda.gov&quot;</a> (PDF). Archived from <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on November 6, 2015.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Chahine EB, Ferrill MJ, Poulakos MN (2010). &quot;Doripenem: a new carbapenem antibiotic&quot;. <em>Am J Health Syst Pharm</em>. <strong>67</strong> (23): 2015â€“24. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2146%2Fajhp090672" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2146/ajhp090672</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21098373" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21098373</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y (2014). &quot;Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials&quot;. <em>J Chemother</em>. <strong>28</strong> (1): 28â€“36. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1179%2F1973947814Y.0000000226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1179/1973947814Y.0000000226</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25407221" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25407221</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:36170846" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36170846</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hazra, Saugata; Xu, Hua; Blanchard, John (Jun 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tebipenem, a New Carbapenem Antibiotic is a Slow Substrate that Inhibits the Î²-Lactamase from Mycobacterium tuberculosis&quot;</a>. <em>Biochemistry</em>. <strong>53</strong> (22): 3671â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1021%2Fbi500339j" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1021/bi500339j</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4053071</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24846409" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24846409</a>.</span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213972Orig1s000ltr.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213972Orig1s000ltr.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213972Orig1s000ltr.pdf</a></span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">George, John (21 September 2010). <a href="http://www.biovalley.com/content.cfm?nav=6&amp;content=19&amp;command=details&amp;id=15100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Novartis shutters Protez&quot;</a>. <em>BioValley</em>.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE (2011). <a href="https://doi.org/10.1093%2Fcid%2Fciq257" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases&quot;</a>. <em>Clin. Infect. Dis</em>. <strong>52</strong> (5): e103â€“20. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fcid%2Fciq257" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/cid/ciq257</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21292654" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21292654</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE (2010). <a href="https://doi.org/10.1086%2F650482" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America&quot;</a>. <em>Clin. Infect. Dis</em>. <strong>50</strong> (5): 625â€“63. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F650482" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/650482</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20175247" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20175247</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O&#x27;Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). &quot;Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America&quot;. <em>Surg Infect (Larchmt)</em>. <strong>11</strong> (1): 79â€“109. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1089%2Fsur.2009.9930" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1089/sur.2009.9930</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20163262" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20163262</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Infectious Diseases Society of America (2005). &quot;Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia&quot;. <em>Am. J. Respir. Crit. Care Med</em>. <strong>171</strong> (4): 388â€“416. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1164%2Frccm.200405-644ST" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1164/rccm.200405-644ST</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15699079" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15699079</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Delgado-Valverde M, Sojo-Dorado J, Pascual A, RodrÃ­guez-BaÃ±o J (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Clinical management of infections caused by multidrug-resistant Enterobacteriaceae&quot;</a>. <em>Ther Adv Infect Dis</em>. <strong>1</strong> (2): 49â€“69. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1177%2F2049936113476284" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1177/2049936113476284</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4040721</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25165544" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25165544</a>.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Denisuik AJ, LagacÃ©-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG (2013). <a href="https://doi.org/10.1093%2Fjac%2Fdkt027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Molecular epidemiology of extended-spectrum Î²-lactamase-, AmpC Î²-lactamase- and carbapenemase-producing <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11&quot;</a>. <em>J. Antimicrob. Chemother</em>. <strong>68</strong> (Suppl 1): i57â€“65. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdkt027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dkt027</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23587779" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23587779</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Antimicrobial Resistance in Europe 2013&quot;</a> (PDF). <em>ecdc.europa.eu</em>. European Centre for Disease Prevention and Control. 2013. p. 21. Retrieved 7 April 2022.</span></div></li><li id="https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf</a></span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Giske CG (2015). <a href="https://doi.org/10.1016%2Fj.cmi.2015.05.022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin&quot;</a>. <em>Clin. Microbiol. Infect</em>. <strong>21</strong> (10): 899â€“905. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cmi.2015.05.022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cmi.2015.05.022</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26027916" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26027916</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ghaith, Doaa M.; Mohamed, Zeinat K.; Farahat, Mohamed G.; Aboulkasem Shahin, Walaa; Mohamed, Hadeel O. (2019-03-01). <a href="http://www.sciencedirect.com/science/article/pii/S168719791930005X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Colonization of intestinal microbiota with carbapenemase-producing Enterobacteriaceae in paediatric intensive care units in Cairo, Egypt&quot;</a>. <em>Arab Journal of Gastroenterology</em>. <strong>20</strong> (1): 19â€“22. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ajg.2019.01.002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ajg.2019.01.002</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1687-1979" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1687-1979</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30733176" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30733176</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:73444389" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">73444389</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rice LB (2006). <a href="https://doi.org/10.1086%2F504487" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa&quot;</a>. <em>Clin. Infect. Dis</em>. <strong>43</strong> (Suppl 2): S100â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F504487" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/504487</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16894511" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16894511</a>.</span></div></li><li id="40" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Morita Y, Tomida J, Kawamura Y (2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Responses of Pseudomonas aeruginosa to antimicrobials&quot;</a>. <em>Front Microbiol</em>. <strong>4</strong> : 422. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3389%2Ffmicb.2013.00422" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3389/fmicb.2013.00422</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3884212</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24409175" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24409175</a>.</span></div></li><li id="41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">{{Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014;9(6):e99101. Published 2014 Jun 9. doi:10.1371/journal.pone.0099101}}</span></div></li><li id="https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/</a></span></div></li><li id="https://www.biospace.com/press-releases/pivot-po-phase-3-data-show-tebipenem-hbrs-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/press-releases/pivot-po-phase-3-data-show-tebipenem-hbrs-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/press-releases/pivot-po-phase-3-data-show-tebipenem-hbrs-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Carbapenem" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh" id="_R_" async=""></script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Carbapenem\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Carbapenem\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Carbapenem\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T47fc,"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"# Carbapenems\n\n**Carbapenems** are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are generally resistant to many beta-lactamases that inactivate other beta-lactam antibiotics.\n\nCarbapenem antibiotics were originally developed at Merck \u0026 Co. from the carbapenem thienamycin, a naturally derived product of _Streptomyces cattleya_.[1][2] Ongoing global concern exists over the continued increase in rates of resistance to carbapenems, as there are few therapeutic options for treating infections caused by carbapenem-resistant bacteria (such as _Klebsiella pneumoniae_ and other carbapenem-resistant Enterobacteriaceae[3]).[4][5][6] As of 2023, carbapenem resistance among Enterobacteriaceae in the EU/EEA has risen to a population-weighted mean of 13.3%.[7]\n\n[7]: https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf\n## Medical uses\n\n### Intra-abdominal infections\n\nThe carbapenem ertapenem is one of several first-line agents recommended by the Infectious Diseases Society of America (IDSA) for the empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity in low-risk patients, per 2024 guidelines. Agents with anti-pseudomonal activity, such as imipenem and meropenem, are not recommended for this population to minimize resistance development. Imipenem and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal infections that are healthcare-associated.[](https://www.idsociety.org/practice-guideline/intra-abdominal-infections/)\n\n### Complicated urinary tract infections\n\nA 2020 systematic review and meta-analysis found carbapenems, particularly meropenem, to be effective for complicated urinary tract infections (cUTIs), with high clinical cure rates comparable to newer antibiotics, including in cases with multidrug-resistant pathogens. Earlier 2015 reviews noted limited evidence for optimal regimens but supported efficacy in levofloxacin-resistant *E. coli* infections; however, doripenem is no longer available in many markets, including the US since 2018.[](https://academic.oup.com/ofid/article/9/5/ofaa480/5920690)[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing)\n\n### Pneumonia\n\nThe carbapenems imipenem and meropenem are included among options recommended by the American Thoracic Society (ATS) and IDSA as empiric therapy for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), particularly in late-onset cases or when *Pseudomonas aeruginosa*, *Acinetobacter*, or extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are suspected, per 2016 guidelines. Monotherapy is preferred unless local resistance exceeds 10-20% or the patient is in septic shock; routine combination therapy with an aminoglycoside is not recommended due to toxicity risks.[](https://www.idsociety.org/practice-guideline/hap_vap/)\n\nCarbapenems are infrequently used for community-acquired pneumonia (CAP), as most pathogens (*Streptococcus pneumoniae*, *Haemophilus influenzae*, atypicals, Enterobacteriaceae) respond to narrower agents like fluoroquinolones, amoxicillin, or azithromycin. Imipenem and meropenem may be considered in severe CAP with risk factors for *P. aeruginosa* (e.g., structural lung disease), per 2019 IDSA/ATS guidelines.[](https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST)\n\n### Bloodstream infections\n\nA 2015 meta-analysis concluded that the anti-pseudomonal penicillin-beta-lactamase inhibitor combination piperacillin-tazobactam gives results equivalent to treatment with a carbapenem in patients with sepsis.[11] In 2015, the National Institute for Health and Care Excellence recommended piperacillin-tazobactam as first-line therapy for the treatment of bloodstream infections in neutropenic cancer patients.[12]\n\nFor bloodstream infections known to be due to extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenems are superior to alternative treatments.[13]\n\n### Spectrum of activity\n\nCarbapenems exhibit broad-spectrum activity against gram-negative bacteria and somewhat narrower activity against gram-positive bacteria. For empiric therapy, they are often combined with a second drug for broader gram-positive coverage. Use should be guided by local resistance patterns and antimicrobial stewardship to address rising carbapenem-resistant Enterobacteriaceae (CRE), per 2024 IDSA guidance.[](https://www.idsociety.org/practice-guideline/amr-guidance/)\n\n#### Gram-negative pathogens\n\nThe spectrum of activity of the carbapenems imipenem and meropenem includes most Enterobacteriaceae species, including *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Citrobacter freundii*, *Proteus mirabilis*, and *Serratia marcescens*. Activity is maintained against most strains of *E. coli* and *K. pneumoniae* that are resistant to cephalosporins due to the production of extended-spectrum beta-lactamases. Imipenem and meropenem also exhibit good activity against most strains of *Pseudomonas aeruginosa* and *Acinetobacter* species. The observed activity against these pathogens is especially valued as they are intrinsically resistant to many other antibiotic classes.[4]\n\n#### Gram-positive pathogens\n\nThe spectrum of activity of the carbapenems against gram-positive bacteria is fairly broad, but not as exceptionally so as in the case of gram-negative bacteria. Good activity is seen against methicillin-sensitive strains of *Staphylococcus* species, but many other antibiotics provide coverage for such infections. Good activity is also observed for most *Streptococcus* species, including penicillin-resistant strains. Carbapenems are not highly active against methicillin-resistant *Staphylococcus aureus* or most enterococcal infections because carbapenems do not bind to the penicillin-binding protein used by these pathogens.[4]\n\n#### Other\n\nCarbapenems generally exhibit good activity against anaerobes such as *Bacteroides fragilis*. Like other beta-lactam antibiotics, they lack activity against atypical bacteria, which do not have a cell wall and are thus not affected by cell wall synthesis inhibitors.[4]\n## Contraindications\n\nCarbapenems are contraindicated in patients with prior allergic reactions to beta lactam antibiotics. In addition, as the intramuscular formulations of ertapenem and imipenem are formulated with lidocaine, the intramuscular formulation of these two drugs are contraindicated in patients with prior adverse reactions to lidocaine.[14][15] Furthermore, concomitant use of carbapenems with valproic acid is generally not recommended, as it has been shown to decrease valproic acid concentrations by as much as 90%, potentially leading to breakthrough seizures.[16]\n## Adverse effects\n\nSerious and occasionally fatal allergic reactions can occur in people treated with carbapenems.[17] Seizures are a dose-limiting toxicity for imipenem, while the risk is lower for meropenem.[18] Clostridioides difficile-related diarrhea may occur in people treated with carbapenems or other broad-spectrum antibiotics.[19] Although those with an allergy to penicillin may develop cross-sensitivity to carbapenems, the rate is low (less than 1% in patients with confirmed IgE-mediated penicillin allergy).[20][](https://pubmed.ncbi.nlm.nih.gov/31170539/)\n### Approved for clinical use\n\n* [Imipenem](Imipenem \"Imipenem\"), the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.[21] Imipenem is hydrolyzed in the [mammalian kidney](Mammalian_kidney \"Mammalian kidney\") by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor [cilastatin](Cilastatin \"Cilastatin\").[5] Imipenem is available in both intravenous[22] and intramuscular[23] formulations.\n* [Meropenem](Meropenem \"Meropenem\") is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against gram-positive pathogens, and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of seizures in a phase 2 trial, meropenem is effective for the treatment of bacterial meningitis.[24] A systematic review performed by an employee of the company that markets meropenem concluded that it provides a higher bacterial response and lower adverse event rates than imipenem in people with severe infections, but no difference in mortality rate.[25]\n* [Ertapenem](Ertapenem \"Ertapenem\") is administered once daily as an intravenous infusion or intramuscular injection. It lacks useful activity against the _P. aeruginosa_ and _Acinetobacter_ species, both of which are important causes of hospital-acquired infections.[26]\n* [Doripenem](Doripenem \"Doripenem\"), approved in the United States in 2007, has a spectrum of activity very similar to that of meropenem. Its greater stability in solution allows the use of prolonged infusions and it is somewhat less likely to produce seizures than other carbapenems.[27] However, it was discontinued from the US market in 2014 following FDA warnings about increased mortality risk in ventilator-associated pneumonia, though it remains approved for complicated intra-abdominal and urinary tract infections.\n* [Panipenem/betamipron](Panipenem/betamipron \"Panipenem/betamipron\") (Japanese approval 1993)\n* [Biapenem](Biapenem \"Biapenem\") (Japanese approval 2001) exhibits similar efficacy and adverse event rates as other carbapenems.[28]\n* [Tebipenem](Tebipenem \"Tebipenem\") pivoxil (Japanese approval 2009 for pediatric use) is the first carbapenem whose prodrug form, the pivalyl ester, is orally available.[29]\n* [Faropenem](Faropenem \"Faropenem\") medoxomil, approved in Japan in 1997 and in India in 2003, is an oral penem antibiotic for respiratory and urinary tract infections; it has not been approved in the United States.[](https://en.wikipedia.org/wiki/Faropenem)\n* [Sulopenem](Sulopenem \"Sulopenem\") etzadroxil/probenecid (Orlynvah), approved in the United States in October 2024, is an oral penem for uncomplicated urinary tract infections in adult women caused by susceptible bacteria.[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213972Orig1s000ltr.pdf)\n\n### Unapproved/experimental\n\n* [Razupenem](Razupenem \"Razupenem\") (PZ-601)\n  * PZ-601 is a carbapenem antibiotic currently being tested as having a broad spectrum of activity including strains resistant to other carbapenems. Despite early Phase II promise, Novartis (who acquired PZ-601 in a merger deal with Protez Pharmaceuticals) recently dropped PZ-601, citing a high rate of adverse events in testing.[30]\n* [Lenapenem](Lenapenem \"Lenapenem\")\n* [Tomopenem](Tomopenem \"Tomopenem\")\n* [Thienamycin](Thienamycin \"Thienamycin\") (thienpenem) the first discovered carbapenem\n# Bacterial resistance\n\n## Enterobacteriaceae\n\n_Enterobacteriaceae_ are common pathogens responsible for urinary tract infections,[31][32] abdominal infections,[33] and hospital-acquired pneumonia.[9] Beta lactam resistance in these pathogens is most commonly due to the expression of beta lactamase enzymes.[34]\n\nBetween 2007 and 2011, the percentage of _Escherichia coli_ isolates from Canadian hospitals that produce [extended spectrum beta lactamases](Extended_spectrum_beta-lactamase \"Extended spectrum beta-lactamase\") (ESBL) increased from 3.4% to 4.1%; among _Klebsiella pneumoniae_ isolates ESBL producers increased from 1.5% to 4.0%. These strains are resistant to [third generation cephalosporins](Cephalosporins \"Cephalosporins\") that were developed for the treatment of beta lactamase-producing _Enterobacteriaceae_ and carbapenems are generally regarded as the treatment of choice.[35] More recently, many countries have experienced a dramatic upswing in the prevalence of _Enterobacteriaceae_ that produce both ESBLs and [carbapenemases](Carbapenemase \"Carbapenemase\") such as the Klebsiella pneumoniae carbapenemase (KPC). As of 2013, 70% of Greek _Klebsiella pneumoniae_ isolates were resistant to third generation cephalosporins and 60% were resistant to carbapenems.[36] As of 2023, resistance rates in Greece remain elevated at approximately 81.5% to third-generation cephalosporins and 69.7% to carbapenems, while the EU/EEA population-weighted mean for carbapenem resistance in _K. pneumoniae_ has increased to 13.3% (from 10.4% in 2019), with bloodstream infection incidence rising 57.5% over the same period.[](https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf) The growing prevalence and difficulty of treating such multi-drug resistant _Enterobacteriaceae_ has led to a renaissance of the use of antibiotics such as [colistin](Colistin \"Colistin\"), which was discovered in the 1950s but rarely used until recently due to unattractive levels of toxicity.[37] However, colistin resistance is now emerging, further complicating treatment options. Carbapenem-resistant _Enterobacteriaceae_ (CRE) are designated a critical priority by the World Health Organization due to their global threat.\n\nPrevalence of carbapenem-resistant _Enterobacteriaceae_ in paediatric intensive care units (Cairo, Egypt) was 24% and various genes of carbapenemases were detected in 80% of carbapenem-resistant _Enterobacteriaceae_ with dominance of _bla_ OXA-48.[38]\n\n## _Pseudomonas aeruginosa_ and _Acinetobacter baumannii_\n\nInfections caused by the non-fermenting gram-negative bacteria _Pseudomonas aeruginosa_ and _Acinetobacter baumannii_ are most commonly encountered in hospitalized people. These bacteria exhibit an unusually high level of intrinsic resistance to antibiotics due to their expression of a wide range of resistance mechanisms. Antibiotics cross the outer membrane of _Pseudomonas_ and _Acinetobacter_ approximately 100 times more slowly than they cross the outer membrane of _Enterobacteriaceae_ , due in part to their use of [porins](Porin_\\(protein\\) \"Porin \\(protein\\)\") that can adopt a conformation having a very restricted entry channel. Further, the porin levels may be down-regulated in response to antibiotic exposure. Antibiotic molecules that successfully traverse the porin channels may be removed by efflux pumps. Downregulation of the porin OprD2 is an important contributor to imipenem resistance.[39]\n\nLike the _Enterobacteriaceae_ , _Pseudomonas_ and _Acinetobacter_ can express a wide range of antibiotic-deactivitating enzymes, including beta lactamases. _Pseudomonas_ produces an inducible broad spectrum beta lactamase, AmpC, that is produced in response to beta lactam exposure. The combination of inducible AmpC expression, poor membrane permeability, and efflux pumps make _Pseudomonas_ resistant to most beta lactams. The clinical efficacy of carbapenems in _Pseudomonas_ infection arises in part because, while they are strong inducers of AmpC, they are poor substrates. The identification of _Pseudomonas_ strains that produce beta lactamases capable of cleaving carbapenems has raised increasing concern regarding the potential for an era of untreatable _Pseudomonas_ infections.[40]\n## Structure\n\nCarbapenem (formula \\( C_7 H_7 N O_3 \\), CAS registry number 78854-41-8) is the parent of this class of compounds. The parent is only of theoretical interest. The carbapenems are very similar to the penicillins (penams): the sulfur in penams is replaced with methylene and an unsaturation has been introducedâ€”hence the name of the group, the carbapen*ems*.\n\nCarbapenems are further broken down into groups with ertapenem being the lone member of group 1. Group 2 carbapenems (imipenem, meropenem, and doripenem) are identified by their efficacy with respect to multiresistant gram-negative (MDRGN) bacteria such as _Pseudomonas_ and _Acinetobacter_ species.[41]\n## Biosynthesis\n\nThe carbapenems are thought to share their early biosynthetic steps in which the core ring system is formed. [Malonyl-CoA](Malonyl-CoA \"Malonyl-CoA\") is condensed with [glutamate-5-semialdehyde](Glutamate-5-semialdehyde \"Glutamate-5-semialdehyde\") with concurrent formation of the five-membered ring. Next, a Î²-lactam synthetase uses [ATP](Adenosine_triphosphate \"Adenosine triphosphate\") to form the Î²-lactam and the saturated [carbapenam](Carbapenam \"Carbapenam\") core. Further oxidation and ring inversion provides the basic carbapenem.\n## Administration\n\nDue to their expanded spectra, the desire to avoid generation of resistance and the fact that, in general, they have poor oral bioavailability, they are administered intravenously in hospital settings for more serious infections. As of October 2025, the oral carbapenem prodrug tebipenem HBr has demonstrated non-inferiority to intravenous therapy in a Phase III trial for complicated urinary tract infections, with the trial stopped early for efficacy; regulatory filing is planned for Q4 2025, potentially making it the first approved oral carbapenem.[](https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/)[](https://www.biospace.com/press-releases/pivot-po-phase-3-data-show-tebipenem-hbrs-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis)"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886061377,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** Sneader, Walter (2006). _Drug Discovery-A History_. Wiley. p. 310\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-471-89980-8.\",\"description\":\"1. **^** Sneader, Walter (2006). _Drug Discovery-A History_. Wiley. p. 310\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-471-89980-8.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"** Birnbaum J, Kahan FM, Kropp H, MacDonald JS (June 1985). \\\"Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin\\\". _[American Journal of Medicine](American_Journal_of_Medicine \\\"American Journal of Medicine\\\")_. **78** (6A): 3â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0002-9343(85)90097-X](https://doi.org/10.1016%2F0002-9343%2885%2990097-X). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0002-9343](https://search.worldcat.org/issn/0002-9343). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3859213](https://pubmed.ncbi.nlm.nih.gov/3859213).\",\"description\":\"2. **^** Birnbaum J, Kahan FM, Kropp H, MacDonald JS (June 1985). \\\"Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin\\\". _[American Journal of Medicine](American_Journal_of_Medicine \\\"American Journal of Medicine\\\")_. **78** (6A): 3â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0002-9343(85)90097-X](https://doi.org/10.1016%2F0002-9343%2885%2990097-X). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0002-9343](https://search.worldcat.org/issn/0002-9343). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3859213](https://pubmed.ncbi.nlm.nih.gov/3859213).\",\"url\":\"American_Journal_of_Medicine \\\"American Journal of Medicine\\\"\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** [\\\"Brazil: Klebsiella pneumoniae carbapenemase prompts closing of hospital ICU - Outbreak News Today\\\"](http://outbreaknewstoday.com/brazil-klebsiella-pneumoniae-carbapenemase-prompts-closing-of-hospital-icu-51544/). 2015-07-26.\",\"description\":\"3. **^** [\\\"Brazil: Klebsiella pneumoniae carbapenemase prompts closing of hospital ICU - Outbreak News Today\\\"](http://outbreaknewstoday.com/brazil-klebsiella-pneumoniae-carbapenemase-prompts-closing-of-hospital-icu-51544/). 2015-07-26.\",\"url\":\"http://outbreaknewstoday.com/brazil-klebsiella-pneumoniae-carbapenemase-prompts-closing-of-hospital-icu-51544/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E (2013). \\\"Carbapenems\\\". _J Chemother_. **25** (1): 1â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1179/1973947812Y.0000000032](https://doi.org/10.1179%2F1973947812Y.0000000032). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23433439](https://pubmed.ncbi.nlm.nih.gov/23433439). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [218660238](https://api.semanticscholar.org/CorpusID:218660238).\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ _**d**_ Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E (2013). \\\"Carbapenems\\\". _J Chemother_. **25** (1): 1â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1179/1973947812Y.0000000032](https://doi.org/10.1179%2F1973947812Y.0000000032). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23433439](https://pubmed.ncbi.nlm.nih.gov/23433439). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [218660238](https://api.semanticscholar.org/CorpusID:218660238).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). [\\\"Carbapenems: past, present, and future\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018). _Antimicrob. Agents Chemother_. **55** (11): 4943â€“60\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.00296-11](https://doi.org/10.1128%2FAAC.00296-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3195018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21859938](https://pubmed.ncbi.nlm.nih.gov/21859938).\",\"description\":\"5. ^ _**a**_ _**b**_ Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). [\\\"Carbapenems: past, present, and future\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018). _Antimicrob. Agents Chemother_. **55** (11): 4943â€“60\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.00296-11](https://doi.org/10.1128%2FAAC.00296-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3195018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21859938](https://pubmed.ncbi.nlm.nih.gov/21859938).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Livermore DM, Woodford N (October 2000). \\\"Carbapenemases: a problem in waiting?\\\". _[Current Opinion in Microbiology](Current_Opinion_in_Microbiology \\\"Current Opinion in Microbiology\\\")_. **3** (5): 489â€“95\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1369-5274(00)00128-4](https://doi.org/10.1016%2FS1369-5274%2800%2900128-4). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1369-5274](https://search.worldcat.org/issn/1369-5274). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11050448](https://pubmed.ncbi.nlm.nih.gov/11050448).\",\"description\":\"6. **^** Livermore DM, Woodford N (October 2000). \\\"Carbapenemases: a problem in waiting?\\\". _[Current Opinion in Microbiology](Current_Opinion_in_Microbiology \\\"Current Opinion in Microbiology\\\")_. **3** (5): 489â€“95\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1369-5274(00)00128-4](https://doi.org/10.1016%2FS1369-5274%2800%2900128-4). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1369-5274](https://search.worldcat.org/issn/1369-5274). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11050448](https://pubmed.ncbi.nlm.nih.gov/11050448).\",\"url\":\"Current_Opinion_in_Microbiology \\\"Current Opinion in Microbiology\\\"\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). [\\\"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America\\\"](https://doi.org/10.1086%2F649554). _Clin. Infect. Dis_. **50** (2): 133â€“64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/649554](https://doi.org/10.1086%2F649554). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20034345](https://pubmed.ncbi.nlm.nih.gov/20034345).\",\"description\":\"7. **^** Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). [\\\"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America\\\"](https://doi.org/10.1086%2F649554). _Clin. Infect. Dis_. **50** (2): 133â€“64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/649554](https://doi.org/10.1086%2F649554). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20034345](https://pubmed.ncbi.nlm.nih.gov/20034345).\",\"url\":\"https://doi.org/10.1086%2F649554\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Golan Y (2015). [\\\"Empiric therapy for hospital-acquired, gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526420). _BMC Infect. Dis_. **15** : 313. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s12879-015-1054-1](https://doi.org/10.1186%2Fs12879-015-1054-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4526420](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526420). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26243291](https://pubmed.ncbi.nlm.nih.gov/26243291).\",\"description\":\"8. **^** Golan Y (2015). [\\\"Empiric therapy for hospital-acquired, gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526420). _BMC Infect. Dis_. **15** : 313. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s12879-015-1054-1](https://doi.org/10.1186%2Fs12879-015-1054-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4526420](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526420). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26243291](https://pubmed.ncbi.nlm.nih.gov/26243291).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526420\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ Infectious Diseases Society of America (2005). \\\"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia\\\". _Am. J. Respir. Crit. Care Med_. **171** (4): 388â€“416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1164/rccm.200405-644ST](https://doi.org/10.1164%2Frccm.200405-644ST). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15699079](https://pubmed.ncbi.nlm.nih.gov/15699079).\",\"description\":\"9. ^ _**a**_ _**b**_ Infectious Diseases Society of America (2005). \\\"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia\\\". _Am. J. Respir. Crit. Care Med_. **171** (4): 388â€“416\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1164/rccm.200405-644ST](https://doi.org/10.1164%2Frccm.200405-644ST). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15699079](https://pubmed.ncbi.nlm.nih.gov/15699079).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ (2011). [\\\"Guidelines for the management of adult lower respiratory tract infections--full version\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128977). _Clin. Microbiol. Infect_. **17** (Suppl 6): E1â€“59. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1469-0691.2011.03672.x](https://doi.org/10.1111%2Fj.1469-0691.2011.03672.x). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7128977](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128977). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21951385](https://pubmed.ncbi.nlm.nih.gov/21951385).\",\"description\":\"10. **^** Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ (2011). [\\\"Guidelines for the management of adult lower respiratory tract infections--full version\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128977). _Clin. Microbiol. Infect_. **17** (Suppl 6): E1â€“59. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1469-0691.2011.03672.x](https://doi.org/10.1111%2Fj.1469-0691.2011.03672.x). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7128977](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128977). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21951385](https://pubmed.ncbi.nlm.nih.gov/21951385).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128977\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Shiber S, Yahav D, Avni T, Leibovici L, Paul M (2015). [\\\"Î²-Lactam/Î²-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials\\\"](https://doi.org/10.1093%2Fjac%2Fdku351). _J. Antimicrob. Chemother_. **70** (1): 41â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dku351](https://doi.org/10.1093%2Fjac%2Fdku351). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25261419](https://pubmed.ncbi.nlm.nih.gov/25261419).\",\"description\":\"11. **^** Shiber S, Yahav D, Avni T, Leibovici L, Paul M (2015). [\\\"Î²-Lactam/Î²-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials\\\"](https://doi.org/10.1093%2Fjac%2Fdku351). _J. Antimicrob. Chemother_. **70** (1): 41â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dku351](https://doi.org/10.1093%2Fjac%2Fdku351). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25261419](https://pubmed.ncbi.nlm.nih.gov/25261419).\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdku351\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** National Collaborating Centre for Cancer (UK) (2012). [_Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients - National Library of Medicine - PubMed Health_](https://www.ncbi.nlm.nih.gov/books/NBK299128/). National Institute for Health and Care Excellence: Guidance. National Institute for Health and Clinical Excellence (UK). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26065059](https://pubmed.ncbi.nlm.nih.gov/26065059).\",\"description\":\"12. **^** National Collaborating Centre for Cancer (UK) (2012). [_Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients - National Library of Medicine - PubMed Health_](https://www.ncbi.nlm.nih.gov/books/NBK299128/). National Institute for Health and Care Excellence: Guidance. National Institute for Health and Clinical Excellence (UK). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26065059](https://pubmed.ncbi.nlm.nih.gov/26065059).\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK299128/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012). [\\\"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum Î²-lactamases: a systematic review and meta-analysis\\\"](https://doi.org/10.1093%2Fjac%2Fdks301). _J. Antimicrob. Chemother_. **67** (12): 2793â€“803\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks301](https://doi.org/10.1093%2Fjac%2Fdks301). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22915465](https://pubmed.ncbi.nlm.nih.gov/22915465).\",\"description\":\"13. **^** Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012). [\\\"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum Î²-lactamases: a systematic review and meta-analysis\\\"](https://doi.org/10.1093%2Fjac%2Fdks301). _J. Antimicrob. Chemother_. **67** (12): 2793â€“803\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks301](https://doi.org/10.1093%2Fjac%2Fdks301). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22915465](https://pubmed.ncbi.nlm.nih.gov/22915465).\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdks301\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20170118192239/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf) (PDF) on January 18, 2017.\",\"description\":\"14. **^** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20170118192239/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf) (PDF) on January 18, 2017.\",\"url\":\"https://web.archive.org/web/20170118192239/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** [\\\"www.accessdata.fda.gov\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf) (PDF).M\",\"description\":\"15. **^** [\\\"www.accessdata.fda.gov\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf) (PDF).M\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Herrero, Miranda (2015). \\\"Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?\\\". _European Journal of Paediatric Neurology_. **19** (2): 155â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ejpn.2014.12.010](https://doi.org/10.1016%2Fj.ejpn.2014.12.010). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25578527](https://pubmed.ncbi.nlm.nih.gov/25578527).\",\"description\":\"16. **^** Herrero, Miranda (2015). \\\"Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?\\\". _European Journal of Paediatric Neurology_. **19** (2): 155â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ejpn.2014.12.010](https://doi.org/10.1016%2Fj.ejpn.2014.12.010). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25578527](https://pubmed.ncbi.nlm.nih.gov/25578527).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Torres MJ, Blanca M (2010). \\\"The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams\\\". _Med. Clin. North Am_. **94** (4): 805â€“20, xii. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.mcna.2010.04.006](https://doi.org/10.1016%2Fj.mcna.2010.04.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20609864](https://pubmed.ncbi.nlm.nih.gov/20609864).\",\"description\":\"17. **^** Torres MJ, Blanca M (2010). \\\"The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams\\\". _Med. Clin. North Am_. **94** (4): 805â€“20, xii. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.mcna.2010.04.006](https://doi.org/10.1016%2Fj.mcna.2010.04.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20609864](https://pubmed.ncbi.nlm.nih.gov/20609864).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Slama TG (2008). [\\\"Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734). _Crit Care_. **12** (5): 233. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/cc6994](https://doi.org/10.1186%2Fcc6994). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2592734](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18983709](https://pubmed.ncbi.nlm.nih.gov/18983709).\",\"description\":\"18. **^** Slama TG (2008). [\\\"Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734). _Crit Care_. **12** (5): 233. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/cc6994](https://doi.org/10.1186%2Fcc6994). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2592734](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18983709](https://pubmed.ncbi.nlm.nih.gov/18983709).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592734\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Slimings C, Riley TV (2014). [\\\"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis\\\"](https://doi.org/10.1093%2Fjac%2Fdkt477). _J. Antimicrob. Chemother_. **69** (4): 881â€“91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkt477](https://doi.org/10.1093%2Fjac%2Fdkt477). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24324224](https://pubmed.ncbi.nlm.nih.gov/24324224).\",\"description\":\"19. **^** Slimings C, Riley TV (2014). [\\\"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis\\\"](https://doi.org/10.1093%2Fjac%2Fdkt477). _J. Antimicrob. Chemother_. **69** (4): 881â€“91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkt477](https://doi.org/10.1093%2Fjac%2Fdkt477). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24324224](https://pubmed.ncbi.nlm.nih.gov/24324224).\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdkt477\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** [\\\"Pharmaceutical Sciences CSU Parenteral Antibiotic Allergy cross-sensitivity chart\\\"](https://web.archive.org/web/20160417213010/http://www.vhpharmsci.com/VHFormulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf) (PDF). Vancouver Acute Pharmaceutical Sciences, Vancouver Hospital \u0026 Health Sciences Centre. 2016. Archived from [the original](http://www.vhpharmsci.com/vhformulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf) (PDF) on April 17, 2016. Retrieved May 19, 2017.\",\"description\":\"20. **^** [\\\"Pharmaceutical Sciences CSU Parenteral Antibiotic Allergy cross-sensitivity chart\\\"](https://web.archive.org/web/20160417213010/http://www.vhpharmsci.com/VHFormulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf) (PDF). Vancouver Acute Pharmaceutical Sciences, Vancouver Hospital \u0026 Health Sciences Centre. 2016. Archived from [the original](http://www.vhpharmsci.com/vhformulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf) (PDF) on April 17, 2016. Retrieved May 19, 2017.\",\"url\":\"https://web.archive.org/web/20160417213010/http://www.vhpharmsci.com/VHFormulary/Tools/ANTIBIOTIC%20CROSS-SENSITIVITY%20CHART.pdf\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** [PRIMAXIN (Brand Name Drug) FDA Application No. (NDA) 050587 Drug Details, Drugs@FDA](https://www.accessdata.fda.gov/)\",\"description\":\"21. **^** [PRIMAXIN (Brand Name Drug) FDA Application No. (NDA) 050587 Drug Details, Drugs@FDA](https://www.accessdata.fda.gov/)\",\"url\":\"https://www.accessdata.fda.gov/\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20121016180424/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf) (PDF) on October 16, 2012.\",\"description\":\"22. **^** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20121016180424/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf) (PDF) on October 16, 2012.\",\"url\":\"https://web.archive.org/web/20121016180424/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** [\\\"www.accessdata.fda.gov\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf) (PDF).\",\"description\":\"23. **^** [\\\"www.accessdata.fda.gov\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf) (PDF).\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050630s027lbl.pdf\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Zhanel GG, Simor AE, Vercaigne L, Mandell L (1998). [\\\"Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889). _Can J Infect Dis_. **9** (4): 215â€“28\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/1998/831425](https://doi.org/10.1155%2F1998%2F831425). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3250889](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22346545](https://pubmed.ncbi.nlm.nih.gov/22346545).\",\"description\":\"24. **^** Zhanel GG, Simor AE, Vercaigne L, Mandell L (1998). [\\\"Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889). _Can J Infect Dis_. **9** (4): 215â€“28\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/1998/831425](https://doi.org/10.1155%2F1998%2F831425). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3250889](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22346545](https://pubmed.ncbi.nlm.nih.gov/22346545).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250889\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Edwards SJ, Emmas CE, Campbell HE (2005). \\\"Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections\\\". _Curr Med Res Opin_. **21** (5): 785â€“94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1185/030079905X46223](https://doi.org/10.1185%2F030079905X46223). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15969878](https://pubmed.ncbi.nlm.nih.gov/15969878). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7654496](https://api.semanticscholar.org/CorpusID:7654496).\",\"description\":\"25. **^** Edwards SJ, Emmas CE, Campbell HE (2005). \\\"Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections\\\". _Curr Med Res Opin_. **21** (5): 785â€“94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1185/030079905X46223](https://doi.org/10.1185%2F030079905X46223). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15969878](https://pubmed.ncbi.nlm.nih.gov/15969878). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7654496](https://api.semanticscholar.org/CorpusID:7654496).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20151106073454/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf) (PDF) on November 6, 2015.\",\"description\":\"26. **^** [\\\"www.accessdata.fda.gov\\\"](https://web.archive.org/web/20151106073454/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf) (PDF). Archived from [the original](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf) (PDF) on November 6, 2015.\",\"url\":\"https://web.archive.org/web/20151106073454/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021337s042lbl.pdf\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Chahine EB, Ferrill MJ, Poulakos MN (2010). \\\"Doripenem: a new carbapenem antibiotic\\\". _Am J Health Syst Pharm_. **67** (23): 2015â€“24\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2146/ajhp090672](https://doi.org/10.2146%2Fajhp090672). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21098373](https://pubmed.ncbi.nlm.nih.gov/21098373).\",\"description\":\"27. **^** Chahine EB, Ferrill MJ, Poulakos MN (2010). \\\"Doripenem: a new carbapenem antibiotic\\\". _Am J Health Syst Pharm_. **67** (23): 2015â€“24\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2146/ajhp090672](https://doi.org/10.2146%2Fajhp090672). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21098373](https://pubmed.ncbi.nlm.nih.gov/21098373).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y (2014). \\\"Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials\\\". _J Chemother_. **28** (1): 28â€“36\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1179/1973947814Y.0000000226](https://doi.org/10.1179%2F1973947814Y.0000000226). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25407221](https://pubmed.ncbi.nlm.nih.gov/25407221). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [36170846](https://api.semanticscholar.org/CorpusID:36170846).\",\"description\":\"28. **^** Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y (2014). \\\"Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials\\\". _J Chemother_. **28** (1): 28â€“36\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1179/1973947814Y.0000000226](https://doi.org/10.1179%2F1973947814Y.0000000226). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25407221](https://pubmed.ncbi.nlm.nih.gov/25407221). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [36170846](https://api.semanticscholar.org/CorpusID:36170846).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Hazra, Saugata; Xu, Hua; Blanchard, John (Jun 2014). [\\\"Tebipenem, a New Carbapenem Antibiotic is a Slow Substrate that Inhibits the Î²-Lactamase from Mycobacterium tuberculosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071). _Biochemistry_. **53** (22): 3671â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1021/bi500339j](https://doi.org/10.1021%2Fbi500339j). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4053071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24846409](https://pubmed.ncbi.nlm.nih.gov/24846409).\",\"description\":\"29. **^** Hazra, Saugata; Xu, Hua; Blanchard, John (Jun 2014). [\\\"Tebipenem, a New Carbapenem Antibiotic is a Slow Substrate that Inhibits the Î²-Lactamase from Mycobacterium tuberculosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071). _Biochemistry_. **53** (22): 3671â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1021/bi500339j](https://doi.org/10.1021%2Fbi500339j). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4053071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24846409](https://pubmed.ncbi.nlm.nih.gov/24846409).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** George, John (21 September 2010). [\\\"Novartis shutters Protez\\\"](http://www.biovalley.com/content.cfm?nav=6\u0026content=19\u0026command=details\u0026id=15100). _BioValley_.\",\"description\":\"30. **^** George, John (21 September 2010). [\\\"Novartis shutters Protez\\\"](http://www.biovalley.com/content.cfm?nav=6\u0026content=19\u0026command=details\u0026id=15100). _BioValley_.\",\"url\":\"http://www.biovalley.com/content.cfm?nav=6\u0026content=19\u0026command=details\u0026id=15100\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE (2011). [\\\"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases\\\"](https://doi.org/10.1093%2Fcid%2Fciq257). _Clin. Infect. Dis_. **52** (5): e103â€“20. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/ciq257](https://doi.org/10.1093%2Fcid%2Fciq257). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21292654](https://pubmed.ncbi.nlm.nih.gov/21292654).\",\"description\":\"31. **^** Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE (2011). [\\\"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases\\\"](https://doi.org/10.1093%2Fcid%2Fciq257). _Clin. Infect. Dis_. **52** (5): e103â€“20. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/ciq257](https://doi.org/10.1093%2Fcid%2Fciq257). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21292654](https://pubmed.ncbi.nlm.nih.gov/21292654).\",\"url\":\"https://doi.org/10.1093%2Fcid%2Fciq257\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE (2010). [\\\"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America\\\"](https://doi.org/10.1086%2F650482). _Clin. Infect. Dis_. **50** (5): 625â€“63\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/650482](https://doi.org/10.1086%2F650482). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20175247](https://pubmed.ncbi.nlm.nih.gov/20175247).\",\"description\":\"32. **^** Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE (2010). [\\\"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America\\\"](https://doi.org/10.1086%2F650482). _Clin. Infect. Dis_. **50** (5): 625â€“63\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/650482](https://doi.org/10.1086%2F650482). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20175247](https://pubmed.ncbi.nlm.nih.gov/20175247).\",\"url\":\"https://doi.org/10.1086%2F650482\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). \\\"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America\\\". _Surg Infect (Larchmt)_. **11** (1): 79â€“109\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1089/sur.2009.9930](https://doi.org/10.1089%2Fsur.2009.9930). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20163262](https://pubmed.ncbi.nlm.nih.gov/20163262).\",\"description\":\"33. **^** Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). \\\"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America\\\". _Surg Infect (Larchmt)_. **11** (1): 79â€“109\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1089/sur.2009.9930](https://doi.org/10.1089%2Fsur.2009.9930). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20163262](https://pubmed.ncbi.nlm.nih.gov/20163262).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** Delgado-Valverde M, Sojo-Dorado J, Pascual A, RodrÃ­guez-BaÃ±o J (2013). [\\\"Clinical management of infections caused by multidrug-resistant Enterobacteriaceae\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721). _Ther Adv Infect Dis_. **1** (2): 49â€“69\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/2049936113476284](https://doi.org/10.1177%2F2049936113476284). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4040721](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25165544](https://pubmed.ncbi.nlm.nih.gov/25165544).\",\"description\":\"34. **^** Delgado-Valverde M, Sojo-Dorado J, Pascual A, RodrÃ­guez-BaÃ±o J (2013). [\\\"Clinical management of infections caused by multidrug-resistant Enterobacteriaceae\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721). _Ther Adv Infect Dis_. **1** (2): 49â€“69\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/2049936113476284](https://doi.org/10.1177%2F2049936113476284). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4040721](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25165544](https://pubmed.ncbi.nlm.nih.gov/25165544).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040721\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** Denisuik AJ, LagacÃ©-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG (2013). [\\\"Molecular epidemiology of extended-spectrum Î²-lactamase-, AmpC Î²-lactamase- and carbapenemase-producing _Escherichia coli_ and _Klebsiella pneumoniae_ isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11\\\"](https://doi.org/10.1093%2Fjac%2Fdkt027). _J. Antimicrob. Chemother_. **68** (Suppl 1): i57â€“65. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkt027](https://doi.org/10.1093%2Fjac%2Fdkt027). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23587779](https://pubmed.ncbi.nlm.nih.gov/23587779).\",\"description\":\"35. **^** Denisuik AJ, LagacÃ©-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG (2013). [\\\"Molecular epidemiology of extended-spectrum Î²-lactamase-, AmpC Î²-lactamase- and carbapenemase-producing _Escherichia coli_ and _Klebsiella pneumoniae_ isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11\\\"](https://doi.org/10.1093%2Fjac%2Fdkt027). _J. Antimicrob. Chemother_. **68** (Suppl 1): i57â€“65. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkt027](https://doi.org/10.1093%2Fjac%2Fdkt027). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23587779](https://pubmed.ncbi.nlm.nih.gov/23587779).\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdkt027\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** [\\\"Antimicrobial Resistance in Europe 2013\\\"](http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf) (PDF). _ecdc.europa.eu_. European Centre for Disease Prevention and Control. 2013. p. 21. Retrieved 7 April 2022.\",\"description\":\"36. **^** [\\\"Antimicrobial Resistance in Europe 2013\\\"](http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf) (PDF). _ecdc.europa.eu_. European Centre for Disease Prevention and Control. 2013. p. 21. Retrieved 7 April 2022.\",\"url\":\"http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Giske CG (2015). [\\\"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin\\\"](https://doi.org/10.1016%2Fj.cmi.2015.05.022). _Clin. Microbiol. Infect_. **21** (10): 899â€“905\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cmi.2015.05.022](https://doi.org/10.1016%2Fj.cmi.2015.05.022). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26027916](https://pubmed.ncbi.nlm.nih.gov/26027916).\",\"description\":\"37. **^** Giske CG (2015). [\\\"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin\\\"](https://doi.org/10.1016%2Fj.cmi.2015.05.022). _Clin. Microbiol. Infect_. **21** (10): 899â€“905\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cmi.2015.05.022](https://doi.org/10.1016%2Fj.cmi.2015.05.022). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26027916](https://pubmed.ncbi.nlm.nih.gov/26027916).\",\"url\":\"https://doi.org/10.1016%2Fj.cmi.2015.05.022\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Ghaith, Doaa M.; Mohamed, Zeinat K.; Farahat, Mohamed G.; Aboulkasem Shahin, Walaa; Mohamed, Hadeel O. (2019-03-01). [\\\"Colonization of intestinal microbiota with carbapenemase-producing Enterobacteriaceae in paediatric intensive care units in Cairo, Egypt\\\"](http://www.sciencedirect.com/science/article/pii/S168719791930005X). _Arab Journal of Gastroenterology_. **20** (1): 19â€“22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajg.2019.01.002](https://doi.org/10.1016%2Fj.ajg.2019.01.002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-1979](https://search.worldcat.org/issn/1687-1979). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30733176](https://pubmed.ncbi.nlm.nih.gov/30733176). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [73444389](https://api.semanticscholar.org/CorpusID:73444389).\",\"description\":\"38. **^** Ghaith, Doaa M.; Mohamed, Zeinat K.; Farahat, Mohamed G.; Aboulkasem Shahin, Walaa; Mohamed, Hadeel O. (2019-03-01). [\\\"Colonization of intestinal microbiota with carbapenemase-producing Enterobacteriaceae in paediatric intensive care units in Cairo, Egypt\\\"](http://www.sciencedirect.com/science/article/pii/S168719791930005X). _Arab Journal of Gastroenterology_. **20** (1): 19â€“22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajg.2019.01.002](https://doi.org/10.1016%2Fj.ajg.2019.01.002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-1979](https://search.worldcat.org/issn/1687-1979). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30733176](https://pubmed.ncbi.nlm.nih.gov/30733176). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [73444389](https://api.semanticscholar.org/CorpusID:73444389).\",\"url\":\"http://www.sciencedirect.com/science/article/pii/S168719791930005X\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Rice LB (2006). [\\\"Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa\\\"](https://doi.org/10.1086%2F504487). _Clin. Infect. Dis_. **43** (Suppl 2): S100â€“5. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/504487](https://doi.org/10.1086%2F504487). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16894511](https://pubmed.ncbi.nlm.nih.gov/16894511).\",\"description\":\"39. **^** Rice LB (2006). [\\\"Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa\\\"](https://doi.org/10.1086%2F504487). _Clin. Infect. Dis_. **43** (Suppl 2): S100â€“5. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/504487](https://doi.org/10.1086%2F504487). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16894511](https://pubmed.ncbi.nlm.nih.gov/16894511).\",\"url\":\"https://doi.org/10.1086%2F504487\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** Morita Y, Tomida J, Kawamura Y (2014). [\\\"Responses of Pseudomonas aeruginosa to antimicrobials\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212). _Front Microbiol_. **4** : 422. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fmicb.2013.00422](https://doi.org/10.3389%2Ffmicb.2013.00422). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3884212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24409175](https://pubmed.ncbi.nlm.nih.gov/24409175).\",\"description\":\"40. **^** Morita Y, Tomida J, Kawamura Y (2014). [\\\"Responses of Pseudomonas aeruginosa to antimicrobials\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212). _Front Microbiol_. **4** : 422. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fmicb.2013.00422](https://doi.org/10.3389%2Ffmicb.2013.00422). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3884212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24409175](https://pubmed.ncbi.nlm.nih.gov/24409175).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884212\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"** {{Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014;9(6):e99101. Published 2014 Jun 9. doi:10.1371/journal.pone.0099101}}\",\"description\":\"41. **^** {{Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014;9(6):e99101. Published 2014 Jun 9. doi:10.1371/journal.pone.0099101}}\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"** Kumagai T, Tamai S, Abe T, Hikda M (January 2002). \\\"Current status of oral carbapenem development\\\". _[Current Medicinal Chemistry](Current_Medicinal_Chemistry \\\"Current Medicinal Chemistry\\\")_. **1** (1): 1â€“14\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/1568012023355018](https://doi.org/10.2174%2F1568012023355018). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1568-0126](https://search.worldcat.org/issn/1568-0126).\",\"description\":\"42. **^** Kumagai T, Tamai S, Abe T, Hikda M (January 2002). \\\"Current status of oral carbapenem development\\\". _[Current Medicinal Chemistry](Current_Medicinal_Chemistry \\\"Current Medicinal Chemistry\\\")_. **1** (1): 1â€“14\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/1568012023355018](https://doi.org/10.2174%2F1568012023355018). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1568-0126](https://search.worldcat.org/issn/1568-0126).\",\"url\":\"Current_Medicinal_Chemistry \\\"Current Medicinal Chemistry\\\"\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** Hamilton-Miller, JM (November 2003). [\\\"Chemical and Microbiologic Aspects of Penems, a Distinct Class of Î²-Lactams: Focus on Faropenem\\\"](http://www.medscape.com/viewarticle/464632_2). _[Pharmacotherapy](Pharmacotherapy_\\\\(journal\\\\) \\\"Pharmacotherapy \\\\(journal\\\\)\\\")_. **23** (11): 1497â€“507\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1592/phco.23.14.1497.31937](https://doi.org/10.1592%2Fphco.23.14.1497.31937). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14620395](https://pubmed.ncbi.nlm.nih.gov/14620395). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43705118](https://api.semanticscholar.org/CorpusID:43705118).\",\"description\":\"43. **^** Hamilton-Miller, JM (November 2003). [\\\"Chemical and Microbiologic Aspects of Penems, a Distinct Class of Î²-Lactams: Focus on Faropenem\\\"](http://www.medscape.com/viewarticle/464632_2). _[Pharmacotherapy](Pharmacotherapy_\\\\(journal\\\\) \\\"Pharmacotherapy \\\\(journal\\\\)\\\")_. **23** (11): 1497â€“507\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1592/phco.23.14.1497.31937](https://doi.org/10.1592%2Fphco.23.14.1497.31937). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14620395](https://pubmed.ncbi.nlm.nih.gov/14620395). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43705118](https://api.semanticscholar.org/CorpusID:43705118).\",\"url\":\"http://www.medscape.com/viewarticle/464632_2\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"\\\"Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.\\\"\",\"explanation\":\"This claim contradicts the subsequent paragraph discussing increasing rates of carbapenem resistance. While carbapenems resist many beta-lactamases affecting other beta-lactams, they are susceptible to emerging carbapenemases (e.g., KPC, NDM), making the statement overly absolute and misleading about their vulnerability.\",\"fixedText\":\"Rephrase to clarify that carbapenems are generally resistant to beta-lactamases that hydrolyze penicillins and cephalosporins, but note emerging specific resistances in the resistance paragraph.\",\"evidenceSource\":\"Ref 5; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195018/\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Concern has arisen in recent years over increasing rates of resistance to carbapenems\\\"\",\"explanation\":\"The phrase \\\"recent years\\\" and supporting citations (up to 2015) are outdated as of October 2025. Global surveillance data indicate continued increases in carbapenem resistance through 2023-2025, affecting the currency of the claim.\",\"fixedText\":\"Update phrasing to \\\"Ongoing global concern exists over the continued increase in carbapenem resistance\\\" and add a recent citation for current trends.\",\"evidenceSource\":\"[](https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The introduction lacks temporal context on the persistence and recent escalation of carbapenem resistance, which is essential for understanding the current (2025) public health implications given the article's focus on medical uses and resistance in later sections.\",\"fixedText\":\"Add a brief update: \\\"As of 2023, carbapenem resistance among Enterobacteriaceae in the EU/EEA has increased to 13.3%.\\\" with citation, to provide recent scope and impact without duplicating the dedicated resistance section.\",\"evidenceSource\":\"[](https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf); [](https://journals.lww.com/md-journal/fulltext/2024/12060/global_trends_and_future_directions_on.61.aspx)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The carbapenem ertapenem is one of several first-line agents recommended by the Infectious Disease Society of America for the empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity. Agents with anti-pseudomonal activity, including doripenem, imipenem, and meropenem, are not recommended in this population. Doripenem, imipenem, and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal infections that are hospital-acquired.[7]\\\"\",\"explanation\":\"The cited reference [7] is from 2010 IDSA/SIS guidelines. Updated 2024 IDSA guidelines maintain similar recommendations but emphasize avoiding broad-spectrum anti-pseudomonal agents (imipenem, meropenem, doripenem) in low-risk community-acquired cases to preserve efficacy and reduce resistance. Presenting 2010 recommendations as current without noting updates misleads on current standards.\",\"fixedText\":\"Update to reference 2024 guidelines; clarify recommendations for low-risk vs high-risk; remove or qualify doripenem as it is discontinued in many markets including the US since 2018.\",\"evidenceSource\":\"[][https://www.idsociety.org/practice-guideline/intra-abdominal-infections/]\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"A 2015 systematic review found little evidence that would support the identification of a best antimicrobial regimen for complicated urinary tract infections, but identified three high-quality trials supporting high cure rates with doripenem, including in patients with levofloxacin-resistant E. coli infections.[8]\\\"\",\"explanation\":\"Doripenem was discontinued by the FDA in 2018 due to manufacturing issues and prior safety concerns (e.g., higher mortality in VAP trials). Recommending or highlighting it as effective ignores its unavailability in the US and many markets, potentially misleading on current treatment options.\",\"fixedText\":\"Remove doripenem reference or note discontinuation; update with newer reviews (e.g., 2020 meta-analyses showing efficacy of other carbapenems like meropenem for cUTIs).\",\"evidenceSource\":\"[][https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase producing Enterobacteriaceae are suspected pathogens. Combination therapy, typically with an aminoglycoside, is recommended for Pseudomonas infections to avoid resistance development during treatment.[9]\\\"\",\"explanation\":\"Cited reference [9] is from 2005 IDSA/ATS guidelines. The current 2016 IDSA/ATS guidelines recommend carbapenems (imipenem, meropenem) as options for empiric therapy in HAP/VAP but prefer monotherapy unless high risk of resistance (\u003e10-20%) or septic shock; combination not routinely recommended for Pseudomonas to avoid toxicity, with de-escalation emphasized.\",\"fixedText\":\"Update to 2016 guidelines; adjust to reflect preference for monotherapy in low-resistance settings and avoidance of routine combination therapy.\",\"evidenceSource\":\"[][https://www.idsociety.org/practice-guideline/hap_vap/]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Carbapenems are less commonly used in the treatment of community-acquired pneumonia, as community-acquired strains of the most common responsible pathogens (Streptococcus pneumoniae, Haemophilus influenazae, atypical bacteria, and Enterobactericeace) are typically susceptible to narrower spectrum and/or orally administered agents such as fluoroquinolones, amoxicillin, or azithromycin. Imipenem and meropenem are useful in cases in which P. aeruginosa is a suspected pathogen.[10]\\\"\",\"explanation\":\"Cited reference [10] is from 2011 European guidelines. Updated 2019 IDSA/ATS guidelines for CAP reserve carbapenems for severe cases with risk factors for resistant pathogens (e.g., Pseudomonas in structural lung disease); they are not routinely useful even if P. aeruginosa suspected, as coverage is guided by local patterns and patient history.\",\"fixedText\":\"Update to 2019 guidelines; specify use in severe CAP with Pseudomonas risk factors only.\",\"evidenceSource\":\"[][https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST]\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"The spectrum of activity of the carbapenems imipenem, doripenem, and meropenem includes most Enterobacteriaceace species...\\\"\",\"explanation\":\"Doripenem is included as an active agent, but it has been discontinued in the US since 2018 and is not available in many regions, making its inclusion misleading for current clinical spectrum discussions.\",\"fixedText\":\"Remove doripenem from lists of active carbapenems; focus on currently available ones like imipenem, meropenem, ertapenem.\",\"evidenceSource\":\"[][https://www.federalregister.gov/documents/2018/07/12/2018-14935/concordia-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-29-new-drug-applications]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section lacks updates on resistance]\",\"explanation\":\"The section does not address increasing carbapenem resistance (e.g., CRE rates rising globally as of 2024-2025), which impacts empiric use and stewardship recommendations in current guidelines. This gap affects understanding of applicability in high-resistance settings.\",\"fixedText\":\"Add brief note on role of local resistance patterns and antimicrobial stewardship in guiding carbapenem use, citing recent IDSA AMR guidance (2024).\",\"evidenceSource\":\"[][https://www.idsociety.org/practice-guideline/amr-guidance/]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Seizures are a dose-limiting toxicity for both imipenem and meropenem.[18]\",\"explanation\":\"The cited source indicates a dose-related seizure risk for both, but clarifies the risk is low (\u0026lt;1%) for meropenem (similar to other Î²-lactams) and higher for imipenem, particularly in at-risk patients. Equating them as dose-limiting for both overstates the limitation for meropenem, potentially misleading clinical use.\",\"fixedText\":\"Revise to: \\\"Seizures are a dose-limiting toxicity for imipenem, while the risk is lower for meropenem.[18]\\\"\",\"evidenceSource\":\"[18]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Those with an allergy to penicillin may develop a cross sensitivity to carbapenems.[20]\",\"explanation\":\"The claim is accurate but lacks quantification of the low cross-reactivity rate (â‰ˆ1% in confirmed cases), which is critical for safety as it may lead to unnecessary avoidance of effective therapy in penicillin-allergic patients per current guidelines.\",\"fixedText\":\"Add detail: \\\"Although cross-reactivity occurs, the rate is low (less than 1% in patients with confirmed IgE-mediated penicillin allergy).[20][](https://pubmed.ncbi.nlm.nih.gov/31170539/)\\\"\",\"evidenceSource\":\"[20] and [](https://pubmed.ncbi.nlm.nih.gov/31170539/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Doripenem has a spectrum of activity very similar to that of meropenem. Its greater stability in solution allows the use of prolonged infusions and it is somewhat less likely to produce seizures than other carbapenems.\\\"\",\"explanation\":\"Doripenem was approved in the US in 2007 but the manufacturer discontinued marketing it in the US in 2014 following FDA warnings about increased mortality risk in ventilator-associated pneumonia, although it remains approved for complicated intra-abdominal and urinary tract infections. This omission misrepresents its current availability for clinical use.\",\"fixedText\":\"Add note: Doripenem was approved in the US in 2007 but discontinued from the market in 2014 due to safety concerns in certain indications.\",\"evidenceSource\":\"[](https://www.drugs.com/history/doribax.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Tebipenem (Japanese approval 2015) is the first carbapenem whose prodrug form, the pivalyl ester, is orally available.[29]\\\"\",\"explanation\":\"The cited reference [29] discusses tebipenem's biochemical activity but does not support the 2015 approval date. Tebipenem pivoxil was actually approved in Japan in 2009 for pediatric use as an oral formulation.\",\"fixedText\":\"Correct approval date to 2009 and specify pediatric oral use; update or replace citation if needed.\",\"evidenceSource\":\"[29]; [](https://pubmed.ncbi.nlm.nih.gov/30014729/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Sulopenem is in clinical trials for drug resistant urinary tract infections\\\"\",\"explanation\":\"Sulopenem etzadroxil/probenecid (Orlynvah) was approved by the FDA on October 25, 2024, for uncomplicated urinary tract infections in adult women, making the \\\"in clinical trials\\\" status outdated as of 2025.\",\"fixedText\":\"Move Sulopenem to \\\"Approved for clinical use\\\" subsection with details on 2024 US approval for uUTIs and add appropriate citation.\",\"evidenceSource\":\"[](https://ir.iterumtx.com/press-releases/detail/136/iterum-therapeutics-receives-u-s-fda-approval-of)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"Faropenem\\\"\",\"explanation\":\"Faropenem is listed under unapproved/experimental, but it has been approved and marketed in Japan since 1997 and in India since 2003 for various infections, misrepresenting its global approval status.\",\"fixedText\":\"Move Faropenem to \\\"Approved for clinical use\\\" with note on approvals in Japan (1997) and other countries, but not in the US.\",\"evidenceSource\":\"[](https://en.wikipedia.org/wiki/Faropenem); [](https://newdrugapprovals.org/2021/10/21/faropenem/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"None (section-wide)\",\"explanation\":\"The section lacks mention of recent carbapenem-related approvals, such as sulopenem's 2024 US approval, which fits the examples category and represents a knowledge gap in current developments up to 2025.\",\"fixedText\":\"Add Sulopenem to approved list with approval details.\",\"evidenceSource\":\"[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213972Orig1s000ltr.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The identification of Pseudomonas strains that produce beta lactamases capable of cleaving carbapenems, such as the New Delhi metallo beta lactamase has raised increasing concern regarding the potential for an era of untreatable Pseudomonas infections.[40]\",\"explanation\":\"The cited source [40] (Morita et al. 2014) discusses general resistance mechanisms in Pseudomonas aeruginosa like AmpC and efflux but does not mention New Delhi metallo-beta-lactamase (NDM). NDM is primarily associated with Enterobacteriaceae and is rare in P. aeruginosa, making the example unsupported by the reference.\",\"fixedText\":\"Remove the specific unsupported example \\\"such as the New Delhi metallo beta lactamase\\\" while retaining the general claim about carbapenem-cleaving beta-lactamases, as metallo-beta-lactamases like VIM and IMP are documented in P. aeruginosa.\",\"evidenceSource\":\"[40]; confirmed via article content at https://pmc.ncbi.nlm.nih.gov/articles/PMC3884212/\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"As of 2013, 70% of Greek Klebsiella pneumoniae isolates are resistant to third generation cephalosporins and 60% are resistant to carbapenems.[36]\",\"explanation\":\"The statistic is dated to 2013 and does not reflect subsequent trends; as of 2023, resistance in Greece remains high (approximately 81.5% to third-generation cephalosporins and 69.7% to carbapenems in K. pneumoniae), while EU/EEA average carbapenem resistance in K. pneumoniae has risen to 13.3% from 10.4% in 2019. Lack of update affects the article's currency on a rapidly evolving topic.\",\"fixedText\":\"Update with recent data from 2023, citing the ECDC report, to provide current context without removing historical example.\",\"evidenceSource\":\"ECDC Antimicrobial Resistance Surveillance in Europe 2023 [](https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire subsections lack post-2019 updates.\",\"explanation\":\"The section omits recent global and regional trends in carbapenem resistance, including the WHO designation of carbapenem-resistant Enterobacteriaceae as a critical priority pathogen, rising incidence of CRE in Europe (e.g., 3.97 per 100,000 population for K. pneumoniae bloodstream infections in 2023), emergence of new carbapenemase producers (e.g., increased OXA-48 and metallo-beta-lactamases), and growing colistin resistance, which limits alternatives. This gap leaves the section outdated as of 2025.\",\"fixedText\":\"Add a brief paragraph or sentences at the end of the Enterobacteriaceae subsection summarizing recent trends (2019â€“2023) with citations to authoritative sources like ECDC and WHO.\",\"evidenceSource\":\"ECDC Risk Assessment on CRE (2025 update) [](https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf); WHO Global Priority List of Antibiotic-Resistant Bacteria (2017, reaffirmed 2024)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"However, research is underway to develop an effective oral carbapenem.[42]\",\"explanation\":\"The claim and its supporting citation from 2002 do not reflect developments as of October 2025, when Phase III trial results for the oral carbapenem tebipenem HBr were announced, demonstrating efficacy and leading to a planned Q4 2025 regulatory filing.\",\"fixedText\":\"Update the claim to specify the advanced development of tebipenem HBr, including its Phase III results and planned filing as of October 2025, with new citations.\",\"evidenceSource\":\"[](https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"However, research is underway to develop an effective oral carbapenem.[42]\",\"explanation\":\"Citation [42] from 2002 discusses early development status and cannot verify or support claims about ongoing research in 2025.\",\"fixedText\":\"Remove [42] and replace with current sources supporting the updated claim.\",\"evidenceSource\":\"[42]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section lacks details on specific recent advancements in oral carbapenem development, such as tebipenem HBr's Phase III trial success for complicated urinary tract infections, stopped early for efficacy in May 2025, and its potential as the first approved oral carbapenem if filing succeeds.\",\"fixedText\":\"Add concise details on tebipenem HBr's development status as of October 2025, with citations to authoritative sources like GSK and Spero Therapeutics announcements.\",\"evidenceSource\":\"[](https://www.biospace.com/press-releases/pivot-po-phase-3-data-show-tebipenem-hbrs-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis)\"}],\"slug\":\"Carbapenem\",\"title\":\"Carbapenems\",\"content\":\"$1f\",\"description\":\"Carbapenems\\n\\nCarbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections.\",\"metadata\":{\"categories\":[],\"lastModified\":\"1761553996\",\"contentLength\":\"18428\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"88798\",\"recentViews\":\"88798\",\"dailyAvgViews\":2959.933349609375,\"qualityScore\":1,\"lastViewed\":\"1761886061\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886061375,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Carbapenem\"],\"queryHash\":\"[\\\"page\\\",\\\"Carbapenem\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Carbapenems\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"5\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"6\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Carbapenem\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:title\",\"content\":\"Carbapenems\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:description\",\"content\":\"Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents...\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Carbapenem\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:alt\",\"content\":\"Carbapenems\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"17\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.996Z\"}],[\"$\",\"meta\",\"18\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:title\",\"content\":\"Carbapenems\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:description\",\"content\":\"Carbapenems are a class of highly effective antibiotic agents most commonly used for the treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents...\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"23\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"24\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YjlhOGI0NTEtN2E4MS00YWNjLWFjNzUtOTVlOTdhYmU2MTdh">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Carbapenem\"}]}]\n"])</script></body></html>